These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. Watanabe H; Kosuge K; Nishio S; Yamada H; Uchida S; Satoh H; Hayashi H; Ishizaki T; Ohashi K Life Sci; 2004 Dec; 76(3):281-92. PubMed ID: 15531380 [TBL] [Abstract][Full Text] [Related]
3. Simvastatin-diltiazem drug interaction resulting in rhabdomyolysis and hepatitis. Kanathur N; Mathai MG; Byrd RP; Fields CL; Roy TM Tenn Med; 2001 Sep; 94(9):339-41. PubMed ID: 11550401 [TBL] [Abstract][Full Text] [Related]
4. Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors. Yang SH; Choi JS; Choi DH Pharmacology; 2011; 88(1-2):1-9. PubMed ID: 21709429 [TBL] [Abstract][Full Text] [Related]
5. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs. Davis HR; Pula KK; Alton KB; Burrier RE; Watkins RW Metabolism; 2001 Oct; 50(10):1234-41. PubMed ID: 11586500 [TBL] [Abstract][Full Text] [Related]
6. The interaction of diltiazem with simvastatin. Mousa O; Brater DC; Sunblad KJ; Hall SD Clin Pharmacol Ther; 2000 Mar; 67(3):267-74. PubMed ID: 10741630 [TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Lennernäs H; Fager G Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173 [TBL] [Abstract][Full Text] [Related]
8. [Pharmacology of HMG CoA reductase inhibitors (statins)]. Kostner GM Wien Med Wochenschr; 1999; 149(5-6):120-4. PubMed ID: 10408002 [TBL] [Abstract][Full Text] [Related]
9. Effect of treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on serum coenzyme Q10 in diabetic patients. Miyake Y; Shouzu A; Nishikawa M; Yonemoto T; Shimizu H; Omoto S; Hayakawa T; Inada M Arzneimittelforschung; 1999 Apr; 49(4):324-9. PubMed ID: 10337451 [TBL] [Abstract][Full Text] [Related]
10. Increasing doses of simvastatin versus combined ezetimibe/simvastatin: effect on circulating endothelial progenitor cells. Pesaro AE; Serrano CV; Katz M; Marti L; Fernandes JL; Parra PR; Campos AH J Cardiovasc Pharmacol Ther; 2013 Sep; 18(5):447-52. PubMed ID: 23739650 [TBL] [Abstract][Full Text] [Related]
11. Common genetic variation in the ABCB1 gene is associated with the cholesterol-lowering effect of simvastatin in males. Becker ML; Visser LE; van Schaik RH; Hofman A; Uitterlinden AG; Stricker BH Pharmacogenomics; 2009 Nov; 10(11):1743-51. PubMed ID: 19891551 [TBL] [Abstract][Full Text] [Related]
12. Simvastatin-induced myopathy, the role of interaction with diltiazem and genetic predisposition. Hu M; Mak VW; Tomlinson B J Clin Pharm Ther; 2011 Jun; 36(3):419-25. PubMed ID: 21545622 [TBL] [Abstract][Full Text] [Related]
13. Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. Chang JW; Yang WS; Min WK; Lee SK; Park JS; Kim SB Am J Kidney Dis; 2002 Jun; 39(6):1213-7. PubMed ID: 12046033 [TBL] [Abstract][Full Text] [Related]
14. Effect of simvastatin on trioleylglycerol hydrolysis and transacylation with cholesterol in serum of outpatients with coronary heart disease. Pioruńska-Stolzmann M; Pioruńska-Mikolajczak A; Mikolajczyk Z Drugs Exp Clin Res; 2003; 29(1):37-43. PubMed ID: 12866362 [TBL] [Abstract][Full Text] [Related]
15. Simvastatin and pravastatin equally improve flow-mediated dilation in males with hypercholesterolemia. Sebestjen M; Boh M; Keber I Wien Klin Wochenschr; 2002 Dec; 114(23-24):999-1003. PubMed ID: 12635468 [TBL] [Abstract][Full Text] [Related]
16. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Hsu I; Spinler SA; Johnson NE Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093 [TBL] [Abstract][Full Text] [Related]
17. Low-dose simvastatin is a well-tolerated and efficacious cholesterol-lowering agent in ciclosporin-treated kidney transplant recipients: double-blind, randomized, placebo-controlled study in 40 patients. Arnadottir M; Eriksson LO; Germershausen JI; Thysell H Nephron; 1994; 68(1):57-62. PubMed ID: 7991041 [TBL] [Abstract][Full Text] [Related]
18. Simvastatin decreases nitric oxide overproduction and reverts the impaired vascular responsiveness induced by endotoxic shock in rats. Giusti-Paiva A; Martinez MR; Felix JV; da Rocha MJ; Carnio EC; Elias LL; Antunes-Rodrigues J Shock; 2004 Mar; 21(3):271-5. PubMed ID: 14770041 [TBL] [Abstract][Full Text] [Related]
19. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia. Pappu AS; Bacon SP; Illingworth DR J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170 [TBL] [Abstract][Full Text] [Related]
20. Regulation of vascular tone from spontaneously hypertensive rats by the HMG-CoA reductase inhibitor, simvastatin. Pérez-Guerrero C; Márquez-Martín A; Herrera MD; Marhuenda E; Alvarez de Sotomayor M Pharmacology; 2005 Jul; 74(4):209-15. PubMed ID: 15920353 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]